1. Malignant pleural effusion risk based on a novel tool using homocysteine and carcinoembryonic antigen in pleural fluid: A multicenter study.
- Author
-
Santotoribio JD, Corral-Pérez J, Nuñez-Jurado D, Fatela-Cantillo D, La Torre ÁG, Orantes-Maroto G, Valle-Vázquez LD, Castillo-Otero DD, Maira-Gonzalez N, Cobos-Díaz A, Guerrero JM, and Lopez-Saez JB
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Adult, Homocysteine metabolism, Carcinoembryonic Antigen metabolism, Pleural Effusion, Malignant metabolism, Pleural Effusion, Malignant diagnosis
- Abstract
Introduction: This multicenter study aimed to evaluate the Malignant Pleural Effusion Risk (MPER) diagnostic accuracy in distinguishing between benign and malign pleural effusion., Methods: MPER is based on pleural fluid Homocysteine (HCY) and carcinoembryonic antigen (CEA) that were measured using three different methods. MPER was calculated by assessing a previously published probabilistic model: Probability (%) = 100× (1 + e-z)-1, where Z = 0.5471 × [HCY] + 0.3846 × [CEA]-8.2671., Results: A total of 301 patients were included (140 MPE). MPER demonstrated a high AUC (0.891), sensitivity (84.3 %), and specificity (80.7 %) with a cut-off > 35.3 %., Conclusions: The MPER model demonstrated a high diagnostic accuracy supporting its use as a novel and powerful tool., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.)
- Published
- 2025
- Full Text
- View/download PDF